What's new? Log in Free sign up

Neuphoria Therapeutics (NEUP)

Company Profile

Company profile

Ticker

NEUP

Exchange

Website

www.bionomics.com.au

CEO

Dr. Spyridon Papapetropoulos M.D., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

BIONOMICS LIMITED/FI

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NEUP stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Prospectus supplement for primary offering

Notice of effectiveness

Registration of securities for employees

Shelf registration

27 Jan 25

Notice of effectiveness

Shelf registration (amended)

7 Jan 25

Notice of effectiveness

Notice of effectiveness

Entry into a Material Definitive Agreement

Latest ownership filings

View all

ARMISTICE CAPITAL, LLC

Lynx1 Capital Management LP

Apeiron Investment Group Ltd.

Peter Miles Winston Davies

Timothy M. Cunningham

David Ian Wilson

Aaron Ngoc Dung Weaver

Spyros Papapetropoulos

Financial summary

Financial statements Chart NEUP financial data

Quarter (USD)	Sep 24	Jun 24	Jun 23	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 24	Jun 23	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)		8.16 mm	8.16 mm	8.16 mm	8.16 mm	8.16 mm
Cash burn (monthly)		(no burn)	1.19 mm	297.31 k	1.48 mm	369.42 k
Cash used (since last report)		n/a	5.04 mm	1.26 mm	6.26 mm	1.56 mm
Cash remaining		n/a	3.13 mm	6.91 mm	1.91 mm	6.60 mm
Runway (months of cash)		n/a	2.6	23.2	1.3	17.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

NEUP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	87	15	+480.0%
Opened positions	75	4	+1775.0%
Closed positions	3	27	-88.9%
Increased positions	0	0
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	242.31 bn	12.25 bn	+1878.1%
Total shares	56.15 mm	13.74 mm	+308.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Lynx1 Capital Management	5.22 mm	$30.56 bn	NEW
EcoR1 Capital	5.00 mm	$29.25 bn	NEW
BLK BlackRock	4.46 mm	$26.10 bn	NEW
Biotechnology Value Fund L P	4.41 mm	$14.08 mm	0.0%
Adage Capital Partners GP, L.L.C.	4.40 mm	$25.74 bn	NEW
BVF	2.99 mm	$17.49 bn	NEW
Baker Bros. Advisors	2.78 mm	$16.29 bn	NEW
Cormorant Asset Management	2.50 mm	$17.05 mm	NEW
Vanguard	2.13 mm	$12.48 bn	NEW
K2 HealthVentures Equity Trust	2.10 mm	$6.93 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Lynx1 Capital Management	5.22 mm	+5.22 mm	NEW
EcoR1 Capital	5.00 mm	+5.00 mm	NEW
BLK BlackRock	4.46 mm	+4.46 mm	NEW
Adage Capital Partners GP, L.L.C.	4.40 mm	+4.40 mm	NEW
BVF	2.99 mm	+2.99 mm	NEW
Baker Bros. Advisors	2.78 mm	+2.78 mm	NEW
Cormorant Asset Management	2.50 mm	+2.50 mm	NEW
Vanguard	2.13 mm	+2.13 mm	NEW
Propel Bio Management	2.09 mm	+2.09 mm	NEW
Deer Management	1.25 mm	+1.25 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $21

HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $8 to $21.

Bionomics Announces Supreme Court Of New South Wales Approves Bionomics' Re-Domiciliation From Australia To The United States

Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court") has today made orders approving the scheme of arrangement in relation to the

Bionomics Approves The Proposed Scheme Of Arrangement In Relation To The Company's Proposed Re-Domiciliation From Australia To The U.S., Under Which Neuphoria Therapeutics, Will Become The Ultimate Parent Company Of Bionomics

Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States.Bionomics shareholders have

Bionomics Publishes The Results From The Phase 2 ATTUNE Study Of BNC210 In Patients With Post-Traumatic Stress Disorder In NEJM Evidence

Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Press releases

From Benzinga Pro

Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court")

Results of Scheme Meeting

ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed

Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting

ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric

Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.